Patents by Inventor Robert Vincent Tuohy, III

Robert Vincent Tuohy, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANHYDROUS CRYSTALLINE FREE BASE FORM OF 6-{2-[1-(6-METHYL-3-PYRIDAZINYL)-4-PIPERIDINYL]ETHOXY}-3-ETHOXY-1,2-BENZISOXAZOLE
    Publication number: 20180162849
    Abstract: A crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is provided which is useful in the treatment of infections caused by Picornaviridae such as human rhinovirus (HRV), and in particular the crystal form is an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole. In addition, a method of manufacturing the free base crystalline form is also provided, including a step of micronizing the compound particles, optionally using a wetting agent, as well as pharmaceutical compositions incorporating the free base crystalline form such as tablets or suspensions, and methods of therapeutic treatments using this form and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 22, 2017
    Publication date: June 14, 2018
    Inventors: Edward LEE, David MCALLISTER, Andrew TRIGWELL, Robert Vincent TUOHY, III, Peter SNYDER, JR., Christa Leisa FRASSETTO
  • Anhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
    Patent number: 9802926
    Abstract: A crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is provided which is useful in the treatment of infections caused by Picornaviridae such as human rhinovirus (HRV), and in particular the crystal form is an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole. In addition, a method of manufacturing the free base crystalline form is also provided, including a step of micronizing the compound particles, optionally using a wetting agent, as well as pharmaceutical compositions incorporating the free base crystalline form such as tablets or suspensions, and methods of therapeutic treatments using this form and pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 31, 2017
    Assignee: AVIRAGEN THERAPEUTICS, INC.
    Inventors: Edward Lee, David McAllister, Andrew Trigwell, Robert Vincent Tuohy, III, Peter Snyder, Jr., Christa Leisa Frassetto